Yes. Topical minoxidil can improve growth in pattern hair loss, but it does not work for everyone. The evidence depends on the formulation, dose and outcome measured; there is no single response percentage that applies to all users. Here is what the trials show, how to assess progress and where oral treatment differs.
Minoxidil was originally developed in the 1970s as an oral antihypertensive — a potent vasodilator for severe, treatment-resistant high blood pressure. Patients on it kept reporting an unusual side effect: new hair growth on the scalp, arms, and face. That observation led to a topical version approved by the FDA in 1988 for male pattern hair loss, and in 1992 for women.
The exact mechanism for hair growth is still not fully understood. It appears to open potassium channels in follicle cells, increase local blood flow to the dermal papilla, and — most importantly — prolong the anagen (growth) phase of the hair cycle while shortening the telogen (resting) phase. The net result is more hairs growing at any one time, and existing thin hairs becoming thicker and pigmented.
Olsen and colleagues studied 393 men for 48 weeks, comparing 5% topical solution with 2% solution and placebo. The 5% group had 45% more hair regrowth than the 2% group at week 48. That is a comparison between treatments, not a 45% increase above each person’s starting hair count and not a universal chance of response. Read the trial.
In a 2024 randomized trial, 90 men were assigned to oral minoxidil 5 mg daily or topical 5% minoxidil twice daily; 68 completed 24 weeks. Oral treatment was not superior on the primary hair-density outcomes. A secondary photographic assessment favored oral treatment at the vertex. This does not establish that oral treatment is better overall, or that every lower oral dose is equivalent. Read the randomized trial.
The useful takeaway is that minoxidil can help, but photographs, tolerability and the correct diagnosis matter more than a promised percentage. Stabilizing loss may also be valuable, even without dramatic regrowth.
Topical 5% foam or solution. Follow the exact product label. Men’s 5% products are labeled for thinning at the crown (vertex), not frontal baldness or a receding hairline. The men’s foam dose is half a capful twice daily; women’s 5% foam has a different once-daily label. Use outside the labeled area is a separate clinical discussion. Men’s foam instructions.
Topical 2% (women's formulation). Slightly less effective than 5% but with lower rates of scalp irritation and facial hair growth — a reasonable choice for women who are sensitive to the 5%.
Low-dose oral minoxidil. Hair-loss treatment with the tablet is off-label in the United States. Bidwell clinicians may select 1.25 to 5 mg daily; standard listed plans use 2.5 mg. The prescription depends on history, tolerability and response. Higher doses are associated with more unwanted facial or body hair, swelling and cardiovascular symptoms, including a fast heartbeat. Do not adjust your own dose. Dose-related evidence.
Minoxidil works most reliably for:
It works less well for advanced balding (Norwood 6–7), scarring alopecias (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia), and non-pattern causes of shedding like telogen effluvium, thyroid disease, iron deficiency, and post-COVID shedding. For those, the cause itself needs treating — minoxidil may still be added later, but alone it won't solve the problem.
Before starting: confirm the likely cause and product directions, and take baseline photographs. Do not self-treat sudden or patchy loss.
Early shedding: a temporary increase can occur, but it does not prove treatment is working. The men’s foam leaflet says to see a physician if increased shedding continues beyond two weeks. Do not wait 12 weeks to report marked or persistent loss. Read the shedding guide.
By four months: the men’s 5% foam label says to stop and ask a doctor if there is no regrowth. That product instruction is not a universal oral-minoxidil stopping rule.
Later follow-up: compare consistent photographs and review adverse effects. A clinician can distinguish limited regrowth from stable density or a different cause of loss.
Six to twelve months: some patients continue improving, but there is no guaranteed month of peak response. Reassess the plan if benefit is inadequate.
Longer term: benefit usually requires continued use. Review safety and ongoing value periodically with your clinician. Treatment follow-up guide.
For selected adult men, a clinician may combine finasteride and minoxidil because they act differently. Combination treatment is not automatically the best choice for everyone and adds each medicine’s precautions. Finasteride is contraindicated in pregnancy; people who are or could be pregnant must not handle crushed or broken tablets. Bidwell’s hair-loss service is for adult men.
Topical products can cause scalp irritation or unwanted facial hair. Follow the product’s stop-use warnings for chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain or swelling. Severe or ongoing chest pain, severe breathing difficulty or collapse needs emergency help: call 911. Increased shedding beyond two weeks needs a physician’s assessment under the men’s foam leaflet. Read the full label.
Oral minoxidil has systemic risks. Its tablet label carries a boxed warning for fluid around the heart (pericardial effusion), sometimes progressing to tamponade, and possible worsening of angina. Low hair-loss doses do not remove these warnings. New swelling, rapid heartbeat, dizziness or sudden weight gain needs prompt assessment; stop the medicine pending medical advice. Call 911 for severe or ongoing chest pain, severe breathing difficulty or fainting. Tablet label.
Topical treatment is available without a prescription, but the right product depends on the person and diagnosis. Oral treatment requires an individual benefit-risk assessment, not just a preference for pills. Tell the prescriber about heart or kidney disease, blood-pressure medicines and other treatments.
Minoxidil is an evidence-based option for pattern hair loss. Choose the formulation with a clinician when needed, measure progress consistently and take adverse effects seriously. Oral treatment has not shown overall superiority to topical treatment in the 2024 trial, and neither form guarantees regrowth.